Cidara Therapeutics, Inc. (NASDAQ:CDTX) to Post FY2025 Earnings of $12.63 Per Share, HC Wainwright Forecasts

Cidara Therapeutics, Inc. (NASDAQ:CDTX) – Research analysts at HC Wainwright upped their FY2025 earnings per share estimates for Cidara Therapeutics in a research note issued on Thursday, April 25th. HC Wainwright analyst E. Arce now anticipates that the biotechnology company will earn $12.63 per share for the year, up from their prior estimate of $12.60. HC Wainwright currently has a “Buy” rating and a $120.00 target price on the stock. The consensus estimate for Cidara Therapeutics’ current full-year earnings is ($13.00) per share. HC Wainwright also issued estimates for Cidara Therapeutics’ FY2026 earnings at $18.85 EPS and FY2027 earnings at $40.32 EPS.

CDTX has been the topic of a number of other reports. Needham & Company LLC increased their target price on Cidara Therapeutics from $3.00 to $25.00 and gave the stock a “buy” rating in a research note on Thursday. Cantor Fitzgerald reaffirmed an “overweight” rating on shares of Cidara Therapeutics in a report on Tuesday, April 23rd. Finally, WBB Securities reaffirmed a “strong-buy” rating and set a $40.00 price target on shares of Cidara Therapeutics in a report on Thursday. One investment analyst has rated the stock with a hold rating, three have given a buy rating and one has issued a strong buy rating to the stock. According to data from MarketBeat, the company has a consensus rating of “Buy” and an average target price of $71.25.

Cidara Therapeutics Trading Down 2.8 %

NASDAQ CDTX opened at $12.63 on Friday. Cidara Therapeutics has a 12 month low of $10.00 and a 12 month high of $29.60. The stock has a market cap of $57.59 million, a P/E ratio of -2.63 and a beta of 0.98. The stock’s fifty day moving average price is $15.32 and its 200-day moving average price is $15.27.

Institutional Inflows and Outflows

A number of institutional investors have recently bought and sold shares of the company. Raymond James Financial Services Advisors Inc. lifted its holdings in Cidara Therapeutics by 25.2% in the third quarter. Raymond James Financial Services Advisors Inc. now owns 79,119 shares of the biotechnology company’s stock valued at $75,000 after acquiring an additional 15,912 shares during the period. Flagship Harbor Advisors LLC bought a new position in Cidara Therapeutics in the third quarter valued at about $28,000. Finally, Pale Fire Capital SE bought a new position in Cidara Therapeutics in the third quarter valued at about $51,000. Institutional investors own 35.82% of the company’s stock.

About Cidara Therapeutics

Cidara Therapeutics, Inc, a biotechnology company, focuses on the discovery, development, and commercialization of long-acting anti-infectives for the treatment and prevention of infectious diseases and oncology in the United States. The company's lead product candidate is rezafungin acetate, a novel molecule in the echinocandin class of antifungals for the treatment and prevention of invasive fungal infections, including candidemia and invasive candidiasis, which are fungal infections associated with high mortality rates.